Drug Guidance
View all drug guidances and details here.
196 articles
2 June 2026
Pembrolizumab for treating high-risk early-stage triple-negative breast cancer
Condition
Breast
Cancer
Drug guidance
1 June 2026
Gemtuzumab ozogamicin for untreated de novo CD33-positive acute myeloid leukaemia
Condition
Blood and Immune System
Cancer
Drug guidance
1 June 2026
Nivolumab for treating gastroesophageal cancers
Condition
Cancer
Gastrointestinal tract
Drug guidance
1 June 2026
Brentuximab vedotin for treating T-cell lymphoma
Condition
Blood and Immune System
Cancer
Drug guidance
1 June 2026
Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia
Condition
Blood and Immune System
Cancer
-
Drug guidance
1 June 2026
Dabrafenib in combination with trametinib for low-grade glioma and relapsed or refractory high-grade glioma, with BRAF V600E mutations
Condition
Cancer
Neurology
-
Drug Guidance
1 June 2026
Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia
Condition
Blood and Immune System
Cancer
-
Drug guidance
1 June 2026
Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer
Condition
Cancer
Endocrine and metabolic
Drug guidance
1 June 2026
Lenvatinib and sorafenib for treating differentiated thyroid cancer
Condition
Cancer
Endocrine and metabolic
Drug guidance
1 June 2026
Lenvatinib and sorafenib for treating advanced hepatocellular carcinoma
Condition
Cancer
Liver
Drug guidance